Viridian Therapeutics, Inc\de 8-K filings

Viridian Therapeutics announced positive clinical trial progress, financial results for 2023, and a successful capital raise extending their operational runway into the second half of 2026.

Viridian Therapeutics has entered into an underwriting agreement to sell 7,142,858 shares of common stock at $21.00 per share, raising approximately $150 million to fund operations into the second half of 2026.